Eli Lilly Australia

62 PBAC submissions on file, active 2005–2025. 70% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Abemaciclib
  Oncology · Recommended with restriction · 2023$46M
• Teriparatide
  Endocrinology · Recommended · 2025other sponsor
• Atomoxetine hydrochloride
  Neurology · Recommended with restriction · 2008—
• Ixekizumab
  Rheumatology · Recommended with restriction · 2023—
• Baricitinib
  Dermatology · Recommended with restriction · 2021—
• Dulaglutide
  Endocrinology · Recommended with restriction · 2022other sponsor
• Exenatide
  Endocrinology · Recommended with restriction · 2019other sponsor
• Galcanezumab
  Neurology · Recommended with restriction · 2022—
• Pemetrexed
  Oncology · Recommended · 2023other sponsor
• Tirzepatide
  Endocrinology · Recommended with restriction · 2025—
• Duloxetine hydrochloride
  Mental health · Recommended with restriction · 2008—
• Insulin glargine
  Endocrinology · Recommended · 2018other sponsor
• Ramucirumab
  Oncology · Not recommended · 2019—
• Selpercatinib
  Oncology · Recommended with restriction · 2024—
• Donanemab
  Neurology · Recommended with restriction · 2025—
• Insulin lispro
  Endocrinology · Recommended · 2017—
• Lebrikizumab
  Dermatology · Recommended with restriction · 2024—
• Mirikizumab
  Gastroenterology · Recommended with restriction · 2023—
• Olanzapine pamoate monohydrate
  Psychiatry · Recommended with restriction · 2009—
• Pemetrexed disodium
  Oncology · Not recommended · 2005—
• Pioglitazone hydrochloride
  Diabetes · Recommended with restriction · 2007—
• Prasugrel
  Cardiovascular · Recommended with restriction · 2024other sponsor
• Tadalafil
  Cardiovascular · Recommended · 2024other sponsor
• Testosterone
  Women's health · Not recommended · 2025other sponsor

Therapy area mix

Activity by year

2005 (3) · 2006 (6) · 2007 (5) · 2008 (6) · 2009 (3) · 2010 (1) · 2011 (3) · 2015 (2) · 2016 (1) · 2017 (4) · 2018 (3) · 2019 (4) · 2020 (4) · 2021 (3) · 2022 (3) · 2023 (6) · 2024 (3) · 2025 (2)

Rejection patterns

Across 15 Not recommended decisions on file.

• 2×insufficient rigor in clinical trial data analysis
• 1×Immature OS data with no observed OS benefit
• 1×modest IDFS benefit
• 1×uncertain long-term extrapolation due to small number of observed events
• 1×treatment effect duration assumptions not well justified